Agilent Technologies (A) Earnings Date & Reports

Key Takeaways

• Agilent reported third-quarter fiscal 2026 revenue of $1.88 billion, up 8.1% reported and 7.3% on a core basis.
• Adjusted earnings per share (EPS) of $1.62 beat the $1.49 analyst consensus by $0.13, and included a $0.06 net benefit from tariff refunds.
• The company raised its full-year fiscal 2026 revenue and adjusted EPS guidance, citing improving end markets and operational momentum.
• Pharma revenue grew 12%, China revenue rose 9%, and the Advanced Therapeutics Division grew nearly 30%.
• Adjusted operating margin expanded 320 basis points (bps) year over year to 28.3%.

Earnings Context and Why It Matters

Agilent Technologies is a leading provider of analytical instruments, laboratory software, consumables, and services used across pharmaceuticals, diagnostics, chemicals, and applied markets. Its quarterly results serve as a closely watched barometer for laboratory equipment spending and broader life-sciences demand. Heading into this report, investors were focused on whether improving biotech funding, a rebound in China, and a replacement cycle for liquid and gas chromatography instruments would sustain the company's recovery. The third quarter ended July 31, 2026, represented a key test of that momentum, and the results carried added weight given management's push to expand margins through its Ignite Operating System.

Reported Results

For the third quarter of fiscal year 2026, Agilent reported revenue of $1.88 billion, up 8.1% on a reported basis and 7.3% on a core (organic, constant-currency) basis, exceeding the high end of its guidance range by 140 bps. GAAP (Generally Accepted Accounting Principles) net income was $362 million, or $1.28 per share, compared with $336 million, or $1.18 per share, a year earlier. Non-GAAP net income was $459 million, or $1.62 per share, up 18% year over year and above the $1.49 consensus. The adjusted figure included a $0.06 net benefit from tariff refunds.

Adjusted operating margin expanded 320 bps year over year to 28.3%. All three reporting segments grew, led by the Life Sciences and Diagnostics Markets Group at $746 million (11% reported growth), while the Agilent CrossLab Group contributed $786 million (6% growth). Pharma revenue rose 12%, chemicals and advanced materials grew 7%, and diagnostics and clinical grew 6%, while academia and government declined 3%.

Management also raised its full-year outlook, now projecting fiscal 2026 revenue of $7.49 billion to $7.51 billion and adjusted EPS of $6.18 to $6.21, above the prior $6.06 consensus. Fourth-quarter guidance calls for revenue of $1.98 billion to $2.00 billion and adjusted EPS of $1.71 to $1.74.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Agilent and its life-sciences peers, the AI Screener offers a practical way to surface actionable ideas across the broader sector.

Market Reaction and Investor Sentiment

Agilent shares rose roughly 3% in after-hours trading following the report, reflecting a favorable reaction to the top-and-bottom-line beat and the upwardly revised guidance. Investor sentiment appeared supported by broad-based demand strength, with particular attention paid to the 9% rebound in China, the near-30% growth in the Advanced Therapeutics Division, and the company's tenth consecutive quarter with a book-to-bill ratio at or above 1.0x — a sign that new orders are keeping pace with or exceeding revenue. Analysts also noted that the beat was not solely dependent on tariff refunds, as EPS excluding that benefit still came in above the top of the guided range.

Forward Outlook and Key Factors to Monitor

Agilent's raised guidance signals management's confidence that improving end markets and operational discipline can carry into the remainder of the fiscal year. Investors will be watching several factors closely in the months ahead. First, the durability of the pharma recovery matters most, given that the segment represents roughly 38% of revenue. Smaller and midsize biotech customers have begun increasing spending as funding conditions improve, and continued progress there would support sustained instrument and consumables demand.

Second, the company's new product cycle is an important catalyst. Early demand for the 9500 Triple Quad ICP-MS, the new 8890B and 8860B gas chromatography systems, and the Altura analytical column family has exceeded expectations, and order conversion will be a key metric to monitor. Third, China remains a swing factor; while third-quarter growth of 9% exceeded expectations with minimal government stimulus benefit, the sustainability of that momentum bears watching.

Finally, management has flagged a pharmaceutical reshoring opportunity it estimates at roughly $1 billion through 2030, with revenue expected to begin building in fiscal 2027. Margin expansion from the Ignite Operating System, the pace of consumables and services growth, and any further tariff-refund developments are additional variables that could shape results over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations